MGM-15

Last updated

MGM-15
MGM-15 structure.png
Identifiers
  • methyl (E)-2-[(2S,3S,7aS,12aR,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12,12a,12b-octahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate
CAS Number
PubChem CID
Chemical and physical data
Formula C23H32N2O5
Molar mass 416.518 g·mol−1
3D model (JSmol)
  • CC[C@@H]1CN2CC[C@]3([C@@H]([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)NC4=C3C(=CC=C4)OC)O
  • InChI=1S/C23H32N2O5/c1-5-14-12-25-10-9-23(27)20-17(7-6-8-19(20)29-3)24-21(23)18(25)11-15(14)16(13-28-2)22(26)30-4/h6-8,13-15,18,21,24,27H,5,9-12H2,1-4H3/b16-13+/t14-,15+,18+,21-,23+/m1/s1
  • Key:QXFXDJATKPXTFF-LIMHOZKTSA-N

MGM-15 is an opioid drug which is a semi-synthetic derivative of 7-hydroxymitragynine, a natural product derived from the South-East Asian tree kratom. MGM-15 was first reported in 2014. It is the 1,2-dihydro derivative of 7-hydroxymitragynine and shows higher potency as an agonist of the mu opioid receptor and delta opioid receptor compared to 7-hydroxymitragynine itself. MGM-15 has been sold as a designer drug since early 2025, initially in the USA. The 9-fluoro derivative of MGM-15 is known as MGM-16, and has even higher potency as an opioid agonist with around 240x the potency of morphine in animal studies. [1] [2] [3] [4] [5] [6]

MGM-16 PMID:168277847 MGM-16 structure.png
MGM-16 PMID:168277847

See also

References

  1. Matsumoto K, Narita M, Muramatsu N, Nakayama T, Misawa K, Kitajima M, et al. (March 2014). "Orally active opioid μ/δ dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice". The Journal of Pharmacology and Experimental Therapeutics. 348 (3): 383–392. doi:10.1124/jpet.113.208108. PMC   6067406 . PMID   24345467.
  2. Raffa RB, ed. (2014). Kratom and Other Mitragynines. doi:10.1201/b17666. ISBN   978-1-4822-2519-8.
  3. Chin KY, Mark-Lee WF (2018). "A Review on the Antinociceptive Effects of Mitragyna speciosa and Its Derivatives on Animal Model". Current Drug Targets. 19 (12): 1359–1365. doi:10.2174/1389450118666170925154025. PMID   28950813.
  4. Bhowmik S, Galeta J, Havel V, Nelson M, Faouzi A, Bechand B, et al. (June 2021). "Site selective C-H functionalization of Mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy". Nature Communications. 12 (1) 3858. Bibcode:2021NatCo..12.3858B. doi:10.1038/s41467-021-23736-2. PMC   8219695 . PMID   34158473.
  5. Smith MT, Kong D, Kuo A, Imam MZ, Williams CM (February 2022). "Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources". Journal of Medicinal Chemistry. 65 (3): 1612–1661. doi:10.1021/acs.jmedchem.0c01915. PMID   34995453.
  6. Gour A, Mukhopadhyay S, Henderson A, Awad A, Seabra MA, Pullman M, et al. (September 2025). "From Kratom to Semi-Synthetic Opioids: The Rise and Risks of MGM-15". Drug Testing and Analysis dta.3952. doi:10.1002/dta.3952. PMID   40936282.